Unknown Private Investor's questions to Protalix Biotherapeutics Inc (PLX) leadership • Q1 2025
Question
A private investor sought clarification on the guidance for 'minimal' future R&D revenues from Chiesi and asked for the total remaining value of the Chiesi contract.
Answer
Executive Eyal Rubin explained that historical R&D revenues were from recognizing development funding over time, a process that is now largely complete. He clarified that future revenues on this line would primarily be from potential regulatory milestones, which could total up to $75 million, but are contingent. Rubin further distinguished this from the total potential value of the agreement, including commercial milestones, which could theoretically reach up to $0.5 billion depending on sales performance.